Valuation : Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 7.74B 1.15B 994M 941M 853M 1.6B 110B 1.61B 11.18B 4.3B 56.06B 4.33B 4.24B 177B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 6.9B 1.03B 886M 839M 761M 1.43B 98.25B 1.43B 9.97B 3.83B 49.99B 3.86B 3.78B 158B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.63%
Yield 2024 *
-
Yield 2025 -
27/08 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
14/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/01 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
28/10/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
26/08/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
04/06/25 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
27/05/25 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25/04/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
15/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
13/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
11/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day-2.25%
1 week-11.93%
Current month-20.59%
1 month-10.10%
3 months+28.52%
6 months+2.97%
Current year+13.03%
1 week 3.41
Extreme 3.41
4.11
1 month 3.41
Extreme 3.41
5.1
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 26/12/2022
Corporate Officer/Principal 42 18/04/2018
Corporate Officer/Principal 40 23/05/2019
Director TitleAgeSince
Director/Board Member 53 11/11/2022
Director/Board Member 40 14/03/2025
Chairman 47 06/02/2025
Date Insider Type Main position Quantity % Market Cap. Importance
2/7/25 Sell 587,500 0.0283%
2/7/25 Sell

Director

259,600 0.0125%
2/7/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-11.93%0.00%+54.22% 1.15B
-1.13%-3.11%+13.82%+60.66% 46.21B
-1.13%-5.78%+33.26%+108.13% 38.78B
+0.12%-0.08%+7.12%+78.27% 11.68B
-0.53%-1.37%-13.25%+10.18% 11.55B
-0.38%-2.26%+18.18%+139.63% 9.14B
+0.32%-2.26%+23.08%+34.73% 7.3B
+0.17%-0.74%+13.44%+197.13% 7.15B
-1.00%-5.25%+34.34%-19.63% 7.1B
-3.13%-4.30%-44.88%+11.66% 4.97B
Average -0.89%-3.55%+8.51%+67.50% 14.5B
Weighted average by Cap. -0.87%-3.34%+15.93%+75.49%

Financials

2024 2025
Net sales 2.44B 364M 313M 297M 269M 505M 34.76B 507M 3.53B 1.36B 17.68B 1.37B 1.34B 55.88B 2.14B 318M 274M 260M 235M 442M 30.41B 444M 3.08B 1.19B 15.47B 1.2B 1.17B 48.89B
Net income 233M 34.7M 29.89M 28.31M 25.66M 48.13M 3.31B 48.38M 336M 129M 1.69B 130M 127M 5.33B 377M 56.18M 48.41M 45.83M 41.54M 77.94M 5.37B 78.33M 544M 209M 2.73B 211M 206M 8.63B
Net Debt -509M -75.82M -65.33M -61.86M -56.07M -105M -7.24B -106M -735M -283M -3.69B -285M -279M -11.65B -838M -125M -108M -102M -92.37M -173M -11.93B -174M -1.21B -465M -6.07B -469M -459M -19.19B
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
11/09/26 CNY 3.470 -2.25% 259,722,549
10/09/26 CNY 3.550 -4.05% 309,140,832
09/09/26 CNY 3.700 -8.19% 447,957,558
08/09/26 CNY 4.030 +2.03% 498,219,211
07/09/26 CNY 3.950 +0.25% 326,127,498

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002437 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!